Ligand id: 7081

Name: hydrocodone

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 1
Topological polar surface area 38.77
Molecular weight 299.15
XLogP 1.43
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat severe pain, and as a cough suppressant.
In November 2014 an extended release formulation, Hysingla ER, was approved by the US FDA. Hysingla ER contains hydrocodone bitartrate (PubChem CID 20831824) and is intended for use only where alternative treatment options are ineffective, not tolerated or do not provide adequate pain management. The formulation of Hysingla ER is designed to make it very difficult to be crushed, broken up or dissolved, with the aim of severely limiting its appeal as a substance of prescription opioid abuse via nasal inhalation or injection.
Mechanism Of Action and Pharmacodynamic Effects
Agonist activity at the opioid receptors in the central nervous system (CNS) causes hyperpolarization and reduced neuronal excitability by various mechanisms. See the DrugBank link for further details.